The role of matrix metalloproteinases in infectious corneal ulcers

Simple item page
dc.contributor.authorGarcía-López, Celia
dc.contributor.authorRodríguez-Calvo-de-Mora, Marina
dc.contributor.authorBorroni, Davide
dc.contributor.authorSánchez-González, José María
dc.contributor.authorRomano, Vito
dc.contributor.authorRocha-de-Lossada, Carlos
dc.contributor.institutionDepartment of Doctoral Studies
dc.date.accessioned2025-01-02T11:15:01Z
dc.date.available2025-01-02T11:15:01Z
dc.date.issued2023-09-01
dc.descriptionPublisher Copyright: © 2023 The Author(s)
dc.description.abstractDuring infectious keratitis, the production of collagenolytic and inflammatory substances, along with increased corneal matrix metalloproteinase (MMP) activity, induces the degradation of corneal collagen and may cause postkeratitis complications, such as opacity, thinning, and corneal perforation. MMPs, especially MMP-2 and MMP-9, are overexpressed in infectious keratitis and sustained over time by inflammatory and nonmicrobial mechanisms. The high MMP levels are correlated with excessive corneal destruction in bacterial, herpetic, fungal, and acanthamoeba infections. Nonspecific treatments, such as tetracyclines, particularly doxycycline, or corticosteroids, are used as adjuvants to antimicrobials to alleviate the disproportionate degradation and inflammation of the corneal layers caused by corneal MMPs and decrease the recruitment and infiltration of inflammatory cells. Treatments showing inhibition of specific MMPs (Galardin, ZHAWOC7726), interfering with pro-MMP activation (EDTA, ascorbic acid), or showing anticytokine effect (epigallocatechin-2-gallate, TRAM-34) have been reported. Other treatments show a direct action over corneal collagen structure such as corneal cross-linking or have been associated with reduction of MMP levels such as amniotic membrane grafting. Although the use of these drugs has been shown in studies to be effective in controlling inflammation, especially in experimental ones, robust studies are still needed based on randomized and randomized clinical trials to demonstrate their potential effect as adjuvants in the management of infectious keratitis.en
dc.description.statusPeer reviewed
dc.format.extent11
dc.format.extent2791045
dc.identifier.citationGarcía-López, C, Rodríguez-Calvo-de-Mora, M, Borroni, D, Sánchez-González, J M, Romano, V & Rocha-de-Lossada, C 2023, 'The role of matrix metalloproteinases in infectious corneal ulcers', Survey of Ophthalmology, vol. 68, no. 5, pp. 929-939. https://doi.org/10.1016/j.survophthal.2023.06.007
dc.identifier.doi10.1016/j.survophthal.2023.06.007
dc.identifier.issn0039-6257
dc.identifier.urihttps://dspace.rsu.lv/jspui/handle/123456789/16999
dc.identifier.urlhttp://www.scopus.com/inward/record.url?scp=85164997620&partnerID=8YFLogxK
dc.language.isoeng
dc.relation.ispartofSurvey of Ophthalmology
dc.rightsinfo:eu-repo/semantics/openAccess
dc.subjectCollagenases
dc.subjectCorneal ulcer
dc.subjectKeratitis
dc.subjectKeratitis treatment
dc.subjectMetalloproteinases
dc.subject3.2 Clinical medicine
dc.subject1.1. Scientific article indexed in Web of Science and/or Scopus database
dc.subjectOphthalmology
dc.titleThe role of matrix metalloproteinases in infectious corneal ulcersen
dc.type/dk/atira/pure/researchoutput/researchoutputtypes/contributiontojournal/systematicreview

Files

Original bundle
Now showing 1 - 1 of 1
No Thumbnail Available
Name:
The_role_of_matrix_metalloproteinases_in_infectious.pdf
Size:
2.66 MB
Format:
Adobe Portable Document Format
Download

Collections

Research outputs from Pure / Zinātniskās darbības rezultāti no ZDIS Pure